Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MPN Advances Day 2019 | Immunotherapy for MPNs: where do we stand?

Bethan Psaila • 15 Nov 2019
MPN Advances Day 2019
Myeloproliferative Neoplasms

Bethan Psaila, MBBS, MRCP, FRCPath, PhD, University of Oxford, Oxford, UK, gives an overview of where we currently stand with immunotherapy in myeloproliferative neoplasms (MPNs), highlighting an exciting new potential target. This interview took place at the MPN Advances Day 2019 in London, UK.

More from Bethan Psaila

1:13
Single-cell multiomics to study malignant megakaryocytes
Bethan Psaila • 15 Nov 2019

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals